Quick Answer
Regencell Bioscience Holdings Ltd reported Operating Income Loss of -$3.77 million for the year ending 2025.
- Regencell Bioscience Holdings Ltd showed an increase of +20.4% in Operating Income Loss from 2024 to 2025.
- This data is from Regencell Bioscience Holdings Ltd's annual report (Form 10-K), filed with the SEC on October 31, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Regencell Bioscience Holdings Ltd's Operating Income Loss has declined by 864.2%.
- Historical annual values: Fiscal year 2025: -$3.77 million | Fiscal year 2024: -$4.74 million | Fiscal year 2023: -$6.27 million | Fiscal year 2022: -$7.62 million | Fiscal year 2021: -$1.38 million | Fiscal year 2020: -$812.4 thousand | Fiscal year 2019: -$391.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: